1. Home
  2. DNLI

as 01-17-2025 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Founded: 2013 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 3.3B IPO Year: 2017
Target Price: $38.91 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 13
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.73 EPS Growth: N/A
52 Week Low/High: $14.56 - $33.33 Next Earning Date: 02-25-2025
Revenue: N/A Revenue Growth: 204.74%
Revenue Growth (this year): -98.23% Revenue Growth (next year): 651.24%

DNLI Daily Stock ML Predictions

Stock Insider Trading Activity of Denali Therapeutics Inc. (DNLI)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Krognes Steve E. DNLI Director Jan 7 '25 Sell $20.81 3,339 $69,484.59 25,757
Schuth Alexander O. DNLI COFO and Secretary Jan 6 '25 Sell $20.52 15,162 $308,290.77 244,308
Krognes Steve E. DNLI Director Dec 31 '24 Sell $20.25 30,000 $607,500.00 25,757
Schenkein David P DNLI Director Nov 11 '24 Sell $32.48 59,441 $1,932,665.05 41,532
Schuth Alexander O. DNLI COFO and Secretary Nov 7 '24 Sell $30.56 15,558 $465,286.44 244,308
SATO VICKI L DNLI Director Nov 7 '24 Sell $30.00 1,020 $30,600.00 111,056
SATO VICKI L DNLI Director Nov 1 '24 Sell $27.07 3,080 $83,375.60 111,056

Share on Social Networks: